文献速递淋巴瘤造血干细胞移植与细胞治疗

抗PD-1治疗后自体干细胞移植治疗多线复发或难治性霍奇金淋巴瘤

Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
PubMed 文献 · Blood Adv · 2021-01-01

该回顾性多中心研究纳入78例接受抗PD-1单抗(单药或联合)作为三线或更后线治疗后行自体干细胞移植(ASCT)的复发/难治性霍奇金淋巴瘤患者。中位随访19.6个月,18个月无进展生存(PFS)率为81%(95%CI 69-89),总生存率为96%(95%CI 87-99);对PD-1无应答者PFS较差(18个月PFS 51%)。

要点

  • 抗PD-1治疗后桥接ASCT在高危复发/难治霍奇金淋巴瘤中显示良好生存。
  • 对PD-1无应答者预后较差,18个月PFS仅51%。
  • 即使化疗难治或移植前PET阳性,ASCT后仍可获较好结局。

核心结论

  • 在高危复发/难治性霍奇金淋巴瘤患者中,抗PD-1治疗后行ASCT与优异的生存结局相关。

研究设计与样本

  • 回顾性多中心研究,纳入22个中心共78例接受抗PD-1单抗(单药或联合)作为三线或更后线治疗后行ASCT的霍奇金淋巴瘤患者。

主要发现

  • 中位ASCT后随访19.6个月,18个月PFS率为81%(95%CI 69-89),OS率为96%(95%CI 87-99)。
  • 对PD-1阻断前连续2种系统治疗难治者18个月PFS为78%,移植前PET阳性者18个月PFS为75%,ASCT前接受≥4种系统治疗者18个月PFS为73%。
  • PD-1无应答者结局较差,18个月PFS为51%。

关键数值与推荐

  • 42例(54%)在抗PD-1治疗前对≥2种连续系统治疗难治。
  • ASCT前中位系统治疗数为4(范围3-7),31例(41%)移植前PET阳性。

临床怎么用

  • 对于多线复发/难治性霍奇金淋巴瘤患者,抗PD-1治疗后桥接ASCT可作为高危及化疗难治患者的治疗选择。

局限性

  • 回顾性研究设计,样本量有限(78例),随访时间较短(中位19.6个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autologous stem cell transplantation (ASCT) can be curative for patients with relapsed/refractory Hodgkin lymphoma (HL). Based on studies suggesting that anti-PD-1 monoclonal antibodies (mAbs) can sensitize patients to subsequent chemotherapy, we hypothesized that anti-PD-1 therapy before ASCT would result in acceptable outcomes among high-risk patients who progressed on or responded insufficiently to ≥1 salvage regimen, including chemorefractory patients who are traditionally considered poor ASCT candidates. We retrospectively identified 78 HL patients who underwent ASCT after receiving an anti-PD-1 mAb (alone or in combination) as third-line or later therapy across 22 centers. Chemorefractory disease was common, including 42 patients (54%) refractory to ≥2 consecutive systemic therapies immediately before anti-PD-1 treatment. Fifty-eight (74%) patients underwent ASCT after anti-PD-1 treatment, while 20 patients (26%) received additional therapy after PD-1 blockade and before ASCT. Patients received a median of 4 systemic therapies (range, 3-7) before ASCT, and 31 patients (41%) had a positive pre-ASCT positron emission tomography (PET) result. After a median post-ASCT follow-up of 19.6 months, the 18-month progression-free survival (PFS) and overall survival were 81% (95% CI, 69-89) and 96% (95% confidence interval [CI], 87-99), respectively. Favorable outcomes were observed for patients who were refractory to 2 consecutive therapies immediately before PD-1 blockade (18-month PFS, 78%), had a positive pre-ASCT PET (18-month PFS, 75%), or received ≥4 systemic therapies before ASCT (18-month PFS, 73%), while PD-1 nonresponders had inferior outcomes (18-month PFS, 51%). In this high-risk cohort, ASCT after anti-PD-1 therapy was associated with excellent outcomes, even among heavily pretreated, previously chemorefractory patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Merryman RW, Redd RA, Nishihori T, et al. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv. 2021. PMID: 33710337. doi:10.1182/bloodadvances.2020003556

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。